Endiya Partners

Endiya Partners is a Hyderabad-based venture firm that positions itself as a co-founder VC for early-stage AI, deep tech, and healthcare startups, with around $100M under management across two funds and a portfolio that has grown to roughly forty-plus companies. The firm writes Seed and Series A checks in the $1M to $5M range, takes meaningful ownership, and is unusually involved at the operating level relative to typical Indian seed funds. Healthcare is a stated pillar rather than an opportunistic sleeve, with portfolio coverage spanning a digital diabetes-management platform, an employee health benefits company, oncology technology, stem-cell therapy, women’s and maternal care, and a single-specialty chronic pain clinic chain. The implication for founders is that Endiya understands hospital sales, doctor adoption, and the Indian payer landscape with more granularity than most generalist firms. The right founder for Endiya is a technical or domain-deep operator building a category-defining business out of India, comfortable with a hands-on partner who will sit in on hiring, GTM, and product reviews. Founders looking for a passive name on the cap table should keep walking. Founders pursuing consumer-only DTC wellness brands, pre-clinical biotech, or anything that requires US FDA-as-the-only-path strategy without an Indian commercial wedge will find Endiya less natural. Geographic advantage is genuine: Hyderabad and Bengaluru talent pools, deep relationships with Indian hospital chains and life-sciences corporates, and a portfolio network that can de-risk early customer conversations. Best path in is a warm intro from a portfolio founder, a co-investor at the Seed stage, or one of the firm’s known LP or scientific advisor relationships. The team also surfaces deals from IIT, IISc, and BITS networks, so a credible technical pedigree helps. In the pitch, lead with the clinical or scientific insight that gives the product a defensible wedge, the realistic commercialization path inside India over the next twenty-four months, and a sober view on hospital integration timelines, which in India still run six to twelve months even for well-priced software. If your story depends on AI or ML, expect Endiya to dig into training data provenance, regulatory positioning under CDSCO, and how you will handle DPDP and patient consent. Caveats: at $1M to $5M check sizes, Endiya is sized for true early stage, so highly capital-intensive theses such as therapeutics or hardware-heavy MedTech will need a co-lead with bigger pockets. Ownership preferences are real, so founders running tight rounds with multiple Tier-1 funds competing should plan for direct conversations about lead structure. Finally, the firm’s hands-on style is a feature for the right CEO and friction for the wrong one; reference current portfolio founders before signing, especially on board cadence and pace of commercial introductions.